Skip to main
LGND

Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target

Ligand Pharmaceuticals (LGND) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ligand Pharmaceuticals Inc. demonstrates a robust financial outlook driven by significant cash inflows that enable further strategic deal-making and foster a unique compounding business model within the smid-cap biotechnology sector. Anticipated strong product launches for Filspari and Ohtuvayre, alongside ongoing growth from established revenue contributors, underline the potential for sustained revenue generation. Additionally, the combination of royalties, licensing payments, and the sale of Captisol material adds diverse revenue streams, enhancing the company's financial stability and growth prospects.

Bears say

The financial outlook for Ligand Pharmaceuticals Inc is tempered by concerns regarding potential underperformance of royalty assets and challenges related to the intellectual property durability of key products. Additionally, the likelihood of clinical-stage royalty assets gaining approval appears uncertain, raising apprehensions about the future commercial viability of these assets. Overall, there is a prevailing sentiment that forthcoming terms for partnerships may prove less favorable than previously anticipated, compounded by the risk that commercial partners may encounter unforeseen obstacles.

Ligand Pharmaceuticals (LGND) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ligand Pharmaceuticals (LGND) Forecast

Analysts have given Ligand Pharmaceuticals (LGND) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Ligand Pharmaceuticals (LGND) has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $243.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $243.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ligand Pharmaceuticals (LGND)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.